-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Biotechnology company Arch Oncology announced today that it presented the latest preclinical data of AO-176 at the American Association for Cancer Research (AACR) annual meeting.
AO-176 is a humanized anti-CD47 IgG2 antibody.
The important thing for immunity is that AO-176 preferentially binds to tumor cells instead of normal cells, and more effectively binds to tumors in an acidic microenvironment (low pH).
Lymphoma
Original source:
Original source:https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here